Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA 2017 | The role of pharmacists in the adoption of novel cancer immunotherapies

Yvonne Summers • 6 Oct 2017
BOPA 2017
General

As traditional treatments for cancer are being surpassed by immunotherapies, the way in which healthcare providers deliver services must change. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from The Christie NHS Foundation Trust, Manchester, UK discusses the transformations facing multidisciplinary teams in dealing with the care of cancer patients receiving immunotherapy. Dr Summers highlights the vital role of the pharmacist in the adoption of novel immunotherapies, particularly in reference to toxicities and patient education.

More from Yvonne Summers

4:28
The changing landscape of NSCLC diagnosis, monitoring and treatment
Yvonne Summers • 6 Oct 2017
2:48
Targeted medicine for ALK-mutated NSCLC
Yvonne Summers • 6 Oct 2017
3:26
The impact of novel NSCLC immunotherapies
Yvonne Summers • 6 Oct 2017

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals